Details of the Drug Combination

General Information of Drug Combination (ID: DC3BBMB)

Drug Combination Name
Lisinopril Prednisolone
Indication
Disease Entry Status REF
Glomerulonephritis Phase 4 [1]
Component Drugs Lisinopril   DMUOK4C Prednisolone   DMQ8FR2
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Lisinopril
Disease Entry ICD 11 Status REF
Chronic heart failure BD1Z Approved [2]
Hypertension BA00-BA04 Approved [3]
Myocardial infarction BA41-BA43 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [4]
High blood pressure BA00 Investigative [2]
Lisinopril Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Angiotensin-converting enzyme (ACE) TTL69WB ACE_HUMAN Inhibitor [7]
HUMAN angiotensin-converting enzyme (ACE) TTGFNPD ACE_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
Lisinopril Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [8]
------------------------------------------------------------------------------------
Lisinopril Interacts with 9 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Angiotensin-converting enzyme (ACE) OTDF1964 ACE_HUMAN Decreases Activity [9]
Renin (REN) OT52GZR2 RENI_HUMAN Increases Expression [10]
Angiotensinogen (AGT) OTBZLYR3 ANGT_HUMAN Decreases Expression [11]
Natriuretic peptides A (NPPA) OTMQNTNX ANF_HUMAN Decreases Expression [11]
Endothelin-1 (EDN1) OTZCACEG EDN1_HUMAN Decreases Secretion [12]
Insulin-like growth factor-binding protein 1 (IGFBP1) OT6UQV2K IBP1_HUMAN Increases Expression [13]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [14]
HLA class I histocompatibility antigen, alpha chain G (HLA-G) OTMLK1KN HLAG_HUMAN Affects Expression [15]
B2 bradykinin receptor (BDKRB2) OTOA9D3W BKRB2_HUMAN Increases ADR [16]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DOT(s)
Indication(s) of Prednisolone
Disease Entry ICD 11 Status REF
Acute adrenal insufficiency N.A. Approved [5]
Acute asthma CA23 Approved [5]
Addison disease 5A74.0 Approved [5]
Allergic rhinitis CA08.0 Approved [5]
Angioedema 4A00.15 Approved [5]
Aspiration pneumonitis N.A. Approved [5]
Autoimmune haemolytic anaemia 3A20 Approved [5]
Blepharoconjunctivitis N.A. Approved [5]
Bursitis N.A. Approved [5]
Cerebral edema 8D60.1 Approved [5]
Chronic graft versus host disease N.A. Approved [5]
Congenital adrenal hyperplasia 5A71.01 Approved [5]
Corneal abrasion NA06.4 Approved [5]
Corneal ulcer 9A76 Approved [5]
Crohn disease DD70 Approved [5]
Dacryocystitis N.A. Approved [5]
Demodex blepharitis 1G07 Approved [5]
Dermatitis herpetiformis EB44 Approved [5]
Diamond-Blackfan anemia N.A. Approved [5]
Disorder of orbital region N.A. Approved [5]
Epicondylitis N.A. Approved [5]
Erythema multiforme N.A. Approved [5]
Exanthem N.A. Approved [5]
Fever MG26 Approved [5]
Granuloma annulare N.A. Approved [5]
Hypersensitivity pneumonitis N.A. Approved [5]
Inflammatory bowel disease DD72 Approved [5]
Ischemia-reperfusion injury DB98.B Approved [5]
Keratitis N.A. Approved [5]
Leukemia N.A. Approved [5]
Lupus nephritis 4A40.0Y Approved [5]
Microscopic polyangiitis N.A. Approved [5]
Miliary tuberculosis N.A. Approved [5]
Mycosis fungoides 2B01 Approved [5]
Myeloproliferative neoplasm 2A20 Approved [5]
Pneumocystis pneumonia CA40.20 Approved [5]
Polymyalgia rheumatica N.A. Approved [5]
Primary cutaneous T-cell lymphoma N.A. Approved [5]
Psoriasis EA90 Approved [5]
Psoriatic arthritis FA21 Approved [5]
Rheumatic heart disease N.A. Approved [5]
Rosacea ED90.0 Approved [5]
Sarcoidosis 4B20.5 Approved [5]
Serum sickness N.A. Approved [5]
Severe asthma CA23 Approved [5]
Skin disease EA00-EM0Z Approved [5]
Solid tumour/cancer 2A00-2F9Z Approved [3]
Sympathetic ophthalmia N.A. Approved [5]
Systemic lupus erythematosus 4A40.0 Approved [5]
Ulcerative colitis DD71 Approved [5]
Multiple sclerosis 8A40 Phase 3 [6]
Acquired thrombocytopenia N.A. Investigative [5]
Asthma CA23 Investigative [5]
Beta-thalassemia major N.A. Investigative [5]
Classic Hodgkin lymphoma N.A. Investigative [5]
Follicular lymphoma 2A80 Investigative [5]
Iridocyclitis N.A. Investigative [5]
Sjogren syndrome 4A43.20 Investigative [5]
Synovitis N.A. Investigative [5]
Uveitis 9A96.Z Investigative [5]
Prednisolone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glucocorticoid receptor (NR3C1) TTYRL6O GCR_HUMAN Modulator [20]
------------------------------------------------------------------------------------
Prednisolone Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [21]
------------------------------------------------------------------------------------
Prednisolone Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [22]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [23]
------------------------------------------------------------------------------------
Prednisolone Interacts with 121 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [24]
CCN family member 1 (CCN1) OTKJBEMD CCN1_HUMAN Increases Expression [17]
Phospholipid phosphatase 3 (PLPP3) OTSSF7BK PLPP3_HUMAN Decreases Expression [17]
Interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) OTPGHZB9 IFIT3_HUMAN Decreases Expression [17]
Calmegin (CLGN) OTEWVFQV CLGN_HUMAN Decreases Expression [17]
D-3-phosphoglycerate dehydrogenase (PHGDH) OT1LMRTG SERA_HUMAN Decreases Expression [17]
Receptor-interacting serine/threonine-protein kinase 2 (RIPK2) OT0KMIYQ RIPK2_HUMAN Decreases Expression [17]
Gasdermin-E (GSDME) OT1ZWY32 GSDME_HUMAN Decreases Expression [17]
Toll-like receptor 2 (TLR2) OTGO5P4R TLR2_HUMAN Decreases Expression [17]
CCN family member 5 (CCN5) OTADU8JJ CCN5_HUMAN Increases Expression [17]
Antiviral innate immune response receptor RIG-I (RIGI) OTFIIC43 RIGI_HUMAN Decreases Expression [17]
2'-5'-oligoadenylate synthase 1 (OAS1) OT8ZLOCY OAS1_HUMAN Decreases Expression [17]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Increases Expression [17]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Decreases Expression [17]
Ubiquitin-like protein ISG15 (ISG15) OT53QQ7N ISG15_HUMAN Decreases Expression [17]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Decreases Expression [17]
Thrombospondin-1 (THBS1) OT0ECWK3 TSP1_HUMAN Increases Expression [17]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Decreases Expression [17]
Hepatocyte growth factor receptor (MET) OT7K55MU MET_HUMAN Decreases Expression [17]
Steryl-sulfatase (STS) OTXTJQPC STS_HUMAN Increases Expression [17]
Neuromedin-B (NMB) OT4NLN6H NMB_HUMAN Decreases Expression [17]
Stromelysin-2 (MMP10) OTJDWW8Q MMP10_HUMAN Decreases Expression [17]
Growth-regulated alpha protein (CXCL1) OT3WCTZV GROA_HUMAN Decreases Expression [17]
Interferon alpha-inducible protein 6 (IFI6) OTWOOAM4 IFI6_HUMAN Decreases Expression [17]
Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) OTXOQDSG IFIT1_HUMAN Decreases Expression [17]
Interleukin-1 receptor antagonist protein (IL1RN) OT308CBE IL1RA_HUMAN Decreases Expression [17]
C-X-C motif chemokine 2 (CXCL2) OTEJCYMY CXCL2_HUMAN Decreases Expression [17]
C-X-C motif chemokine 3 (CXCL3) OTSL94KH CXCL3_HUMAN Decreases Expression [17]
Interferon-induced GTP-binding protein Mx1 (MX1) OT6X8G5T MX1_HUMAN Decreases Expression [17]
Fibulin-1 (FBLN1) OT5MHHOP FBLN1_HUMAN Increases Expression [17]
Atypical chemokine receptor 3 (ACKR3) OTA6GA4F ACKR3_HUMAN Decreases Expression [17]
11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1) OTO7FJA9 DHI1_HUMAN Decreases Expression [17]
Adenosine receptor A2a (ADORA2A) OTVRBZ0I AA2AR_HUMAN Decreases Expression [17]
CCN family member 2 (CCN2) OTC39NSU CCN2_HUMAN Increases Expression [17]
Myristoylated alanine-rich C-kinase substrate (MARCKS) OT7N056G MARCS_HUMAN Decreases Expression [17]
Guanylate-binding protein 1 (GBP1) OTUM7RPJ GBP1_HUMAN Decreases Expression [17]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Decreases Expression [17]
Macrophage metalloelastase (MMP12) OT9Z7LHM MMP12_HUMAN Decreases Expression [17]
Interferon alpha-inducible protein 27, mitochondrial (IFI27) OTI2XGIT IFI27_HUMAN Decreases Expression [17]
Regulator of G-protein signaling 4 (RGS4) OTG94HHL RGS4_HUMAN Decreases Expression [17]
Prolargin (PRELP) OT9EEBUJ PRELP_HUMAN Increases Expression [17]
Spermine synthase (SMS) OT8JYKNH SPSY_HUMAN Decreases Expression [17]
C-X-C chemokine receptor type 4 (CXCR4) OTUFSBX2 CXCR4_HUMAN Decreases Expression [17]
C-C motif chemokine 20 (CCL20) OTUCJY4N CCL20_HUMAN Decreases Expression [17]
DNA-binding protein inhibitor ID-3 (ID3) OTUULW5Z ID3_HUMAN Increases Expression [17]
Tumor necrosis factor alpha-induced protein 2 (TNFAIP2) OTRZH80H TNAP2_HUMAN Decreases Expression [17]
Aldehyde oxidase (AOX1) OT2FZP6H AOXA_HUMAN Increases Expression [17]
Bone marrow stromal antigen 2 (BST2) OTU4LCJV BST2_HUMAN Decreases Expression [17]
EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1) OTZVUOOB FBLN3_HUMAN Increases Expression [17]
Neuronal membrane glycoprotein M6-b (GPM6B) OT8Q1582 GPM6B_HUMAN Increases Expression [17]
Laminin subunit beta-3 (LAMB3) OTFPU6W8 LAMB3_HUMAN Decreases Expression [17]
Nidogen-2 (NID2) OTHC33FF NID2_HUMAN Increases Expression [17]
Signal transducer and activator of transcription 4 (STAT4) OTAK3VFR STAT4_HUMAN Decreases Expression [17]
2'-5'-oligoadenylate synthase-like protein (OASL) OTZ05YRP OASL_HUMAN Decreases Expression [17]
Bcl-2-related protein A1 (BCL2A1) OTWRYSNA B2LA1_HUMAN Decreases Expression [17]
Lymphocyte antigen 6E (LY6E) OTMG16BZ LY6E_HUMAN Decreases Expression [17]
Interferon-induced protein 44-like (IFI44L) OTXKORJP IF44L_HUMAN Decreases Expression [17]
Olfactomedin-like protein 2B (OLFML2B) OTDNJFR4 OLM2B_HUMAN Increases Expression [17]
E3 ubiquitin-protein ligase RNF19B (RNF19B) OTYCWKBP RN19B_HUMAN Decreases Expression [17]
Amphoterin-induced protein 2 (AMIGO2) OTPAIT1O AMGO2_HUMAN Decreases Expression [17]
Probable E3 ubiquitin-protein ligase HERC6 (HERC6) OT7G9PQE HERC6_HUMAN Decreases Expression [17]
Equilibrative nucleobase transporter 1 (SLC43A3) OTR60ZLA S43A3_HUMAN Decreases Expression [17]
Interferon-induced protein 44 (IFI44) OTOKSZVA IFI44_HUMAN Decreases Expression [17]
S-adenosylmethionine-dependent nucleotide dehydratase RSAD2 (RSAD2) OTCA9WCM RSAD2_HUMAN Decreases Expression [17]
Nuclear receptor subfamily 4 group A member 3 (NR4A3) OTPBE9R1 NR4A3_HUMAN Decreases Expression [17]
Type II iodothyronine deiodinase (DIO2) OTGPNSLH IOD2_HUMAN Increases Expression [17]
Interferon regulatory factor 7 (IRF7) OTC1A2PQ IRF7_HUMAN Decreases Expression [17]
Interferon-stimulated gene 20 kDa protein (ISG20) OTCWRJJW ISG20_HUMAN Decreases Expression [17]
Interferon-induced helicase C domain-containing protein 1 (IFIH1) OTZA2AHA IFIH1_HUMAN Decreases Expression [17]
Anthrax toxin receptor 1 (ANTXR1) OT5W1GPC ANTR1_HUMAN Increases Expression [17]
Interleukin-23 subunit alpha (IL23A) OTYO99HC IL23A_HUMAN Decreases Expression [17]
NADH dehydrogenase 1 alpha subcomplex subunit 4-like 2 (NDUFA4L2) OTK0PG7R NUA4L_HUMAN Decreases Expression [17]
Large neutral amino acids transporter small subunit 2 (SLC7A8) OT8XXVO8 LAT2_HUMAN Increases Expression [17]
E3 ISG15--protein ligase HERC5 (HERC5) OTZ5PR39 HERC5_HUMAN Decreases Expression [17]
Paired immunoglobulin-like type 2 receptor alpha (PILRA) OTBE0PLF PILRA_HUMAN Decreases Expression [17]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Decreases Expression [17]
Cytochrome P450 2S1 (CYP2S1) OTKHX4RF CP2S1_HUMAN Decreases Expression [25]
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1) OTCO26FV HMCS1_HUMAN Increases Expression [18]
Inactive phospholipase C-like protein 1 (PLCL1) OTJL2C79 PLCL1_HUMAN Increases Expression [18]
Cyclin-G2 (CCNG2) OTII38K2 CCNG2_HUMAN Increases Expression [18]
Programmed cell death protein 4 (PDCD4) OTZ6NXUX PDCD4_HUMAN Increases Expression [18]
Kelch-like protein 24 (KLHL24) OTWZSX5C KLH24_HUMAN Increases Expression [18]
Protein FAM200C (FAM200C) OTZOXUEK F200C_HUMAN Increases Expression [18]
Arrestin domain-containing protein 3 (ARRDC3) OTAKW7R9 ARRD3_HUMAN Increases Expression [18]
Sulfiredoxin-1 (SRXN1) OTYDBO4L SRXN1_HUMAN Increases Expression [18]
Cysteine-rich motor neuron 1 protein (CRIM1) OTTZNV6Y CRIM1_HUMAN Increases Expression [18]
SLAM family member 5 (CD84) OTAY5B0F SLAF5_HUMAN Increases Expression [18]
PDZ and LIM domain protein 1 (PDLIM1) OT4EGCPG PDLI1_HUMAN Increases Expression [26]
Basic helix-loop-helix ARNT-like protein 1 (BMAL1) OTMI12L2 BMAL1_HUMAN Increases Expression [27]
Period circadian protein homolog 2 (PER2) OTU2B1DJ PER2_HUMAN Decreases Expression [27]
Period circadian protein homolog 1 (PER1) OTVQF3WX PER1_HUMAN Increases Expression [27]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Decreases Expression [28]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Expression [29]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Decreases Expression [26]
Albumin (ALB) OTVMM513 ALBU_HUMAN Increases Expression [30]
Serotransferrin (TF) OT41PEMS TRFE_HUMAN Increases Expression [30]
Glucocorticoid receptor (NR3C1) OTCI2YDI GCR_HUMAN Increases Activity [31]
Insulin-like growth factor I (IGF1) OTIIZR61 IGF1_HUMAN Decreases Response To Substance [32]
Interleukin-4 (IL4) OTOXBWAU IL4_HUMAN Decreases Expression [33]
Interleukin-5 (IL5) OTAFPSCO IL5_HUMAN Decreases Expression [33]
Mineralocorticoid receptor (NR3C2) OT0F2V2Z MCR_HUMAN Increases Activity [31]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Expression [26]
C-C motif chemokine 3 (CCL3) OTW2H3ND CCL3_HUMAN Increases Expression [19]
C-C motif chemokine 4 (CCL4) OT6B8P25 CCL4_HUMAN Increases Expression [19]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [19]
Ganglioside GM2 activator (GM2A) OTIRWZC0 SAP3_HUMAN Increases Expression [26]
Nuclear receptor subfamily 1 group D member 1 (NR1D1) OTJ38PTB NR1D1_HUMAN Decreases Expression [27]
C-X-C chemokine receptor type 2 (CXCR2) OTISGW7L CXCR2_HUMAN Decreases Expression [34]
Long-chain-fatty-acid--CoA ligase 1 (ACSL1) OTB06ESI ACSL1_HUMAN Increases Expression [26]
Growth/differentiation factor 5 (GDF5) OTOV8S81 GDF5_HUMAN Decreases Expression [35]
Tissue factor pathway inhibitor 2 (TFPI2) OTZCRWOR TFPI2_HUMAN Decreases Expression [26]
Transcription factor SOX-9 (SOX9) OTVDJFGN SOX9_HUMAN Decreases Expression [26]
D site-binding protein (DBP) OTE0W7LN DBP_HUMAN Decreases Expression [27]
Cryptochrome-1 (CRY1) OTTGAJT0 CRY1_HUMAN Decreases Expression [27]
Mucin-16 (MUC16) OTHPPE67 MUC16_HUMAN Decreases Expression [36]
Lymphocyte antigen 96 (LY96) OTN4HXA2 LY96_HUMAN Decreases Expression [26]
DNA topoisomerase 1 (TOP1) OT51O0CF TOP1_HUMAN Increases ADR [16]
Histone-lysine N-methyltransferase 2A (KMT2A) OT9GLJI6 KMT2A_HUMAN Decreases Response To Substance [37]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) OTHF4H9U DHI2_HUMAN Increases Metabolism [38]
Mothers against decapentaplegic homolog 1 (SMAD1) OTQSHR25 SMAD1_HUMAN Increases ADR [16]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Increases ADR [16]
------------------------------------------------------------------------------------
⏷ Show the Full List of 121 DOT(s)

References

1 ClinicalTrials.gov (NCT04662723) Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
2 Lisinopril FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Am Heart Assoc. 2020 Apr 7;9(7):e016219.
5 Prednisolone FDA Label
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2866).
7 Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient m... J Atheroscler Thromb. 2009 Jun;16(3):164-71.
8 Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
9 Targeted catalytic inactivation of angiotensin converting enzyme by lisinopril-coupled transition-metal chelates. J Am Chem Soc. 2012 Feb 22;134(7):3396-410. doi: 10.1021/ja208791f. Epub 2012 Feb 10.
10 Hemodynamic responses to converting enzyme inhibition in patients with renal disease. Am J Hypertens. 1989 Aug;2(8):599-603. doi: 10.1093/ajh/2.8.599.
11 Effects of lisinopril on cardiorespiratory, neuroendocrine, and renal function in patients with asymptomatic left ventricular dysfunction. Br Heart J. 1993 Jun;69(6):512-5. doi: 10.1136/hrt.69.6.512.
12 Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-sensitive pathway. Mediators Inflamm. 2008;2008:305087. doi: 10.1155/2008/305087. Epub 2008 Dec 1.
13 Tissue availability of insulin-like growth factor I is inversely related to insulin resistance in essential hypertension: effects of angiotensin converting enzyme inhibition. J Hypertens. 1998 Jun;16(6):863-70. doi: 10.1097/00004872-199816060-00018.
14 Reduced bcl-2 concentrations in hypertensive patients after lisinopril or nifedipine administration. Am J Hypertens. 1999 Jan;12(1 Pt 1):73-5. doi: 10.1016/s0895-7061(98)00217-9.
15 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
16 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
17 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
18 Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
19 Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.
20 Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6.
21 The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol. 2002 Oct;175(1):251-60.
22 Inter-individual difference determinant of prednisolone pharmacokinetics for Japanese renal transplant recipients in the maintenance stage. Xenobiotica. 2009 Dec;39(12):939-45.
23 Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. J Pharmacokinet Biopharm. 1999 Feb;27(1):1-21.
24 Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7.
25 CYP2S1 is negatively regulated by corticosteroids in human cell lines. Toxicol Lett. 2012 Feb 25;209(1):30-4.
26 Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
27 Chronic treatment with prednisolone represses the circadian oscillation of clock gene expression in mouse peripheral tissues. Mol Endocrinol. 2006 Mar;20(3):573-83. doi: 10.1210/me.2005-0165. Epub 2005 Nov 3.
28 Steroid therapy and urinary transforming growth factor-beta1 in IgA nephropathy. Am J Kidney Dis. 2001 Dec;38(6):1191-8. doi: 10.1053/ajkd.2001.29209.
29 Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. Eur J Heart Fail. 2009 May;11(5):463-71. doi: 10.1093/eurjhf/hfp028. Epub 2009 Feb 20.
30 Prednisolone can increase glomerular permeability to proteins in nephrotic syndrome. Kidney Int. 1988 Jun;33(6):1169-74. doi: 10.1038/ki.1988.126.
31 Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol. 2004 Sep;151(3):397-406. doi: 10.1530/eje.0.1510397.
32 Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3. Ann Rheum Dis. 2006 Mar;65(3):301-5. doi: 10.1136/ard.2005.040816. Epub 2005 Aug 3.
33 JTP-27536 [(+)-1,3-dihydroxy-2-hydroxymethylpropyl-2-ammonium 2-[(R)-3-cyclo-hexyl-1-phenylpropyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylate monohydrate], a novel inhibitor of immunoglobulins and interleukin-5 with anti-inflammatory properties in mouse allergic dermatitis model. J Pharmacol Exp Ther. 2005 Jul;314(1):293-301. doi: 10.1124/jpet.104.080846. Epub 2005 Apr 8.
34 CXCR2 Expression on neutrophils is upregulated during the relapsing phase of ocular Behcet disease. Curr Eye Res. 2005 Mar;30(3):195-203. doi: 10.1080/02713680490904331.
35 Modulatory effects of inflammation and therapy on GDF-5 expression in rheumatoid arthritis synovium. Scand J Rheumatol. 2008 Nov-Dec;37(6):401-9. doi: 10.1080/03009740802120010.
36 Dermatomyositis associated with membranous nephropathy in a 43-year-old female. Am J Nephrol. 2002 Jul-Aug;22(4):385-8. doi: 10.1159/000065233.
37 In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia. 2004 Mar;18(3):521-9. doi: 10.1038/sj.leu.2403253.
38 Metabolism of synthetic steroids by the human placenta. Placenta. 2007 Jan;28(1):39-46.